BioTuesdays

Category - Markets

BioSyent

Cormark starts BioSyent at buy

Cormark Securities initiated coverage on BioSyent (TSX-V: RX) with a “buy” recommendation and $10.25 target price. The stock closed at $8.40 on Thursday. BioSyent establishes and builds out pharmaceutical brands in the...

Kura Oncology

Leerink resumes coverage of Kura at outperform

Leerink resumed coverage of Kura Oncology (NASDAQ:KURA) with an “outperform” rating and $15 price target. The stock closed at $5.60 on Wednesday. “We view Kura’s lead pipeline program, tipifarnib (a...

Alcobra Pharmaceuticals

Stifel downgrades Alcobra to hold

Stifel downgraded Alcobra (NASDAQ:ADHD) to “hold” from “buy” and slashed its price target to $3 from $17 after the FDA issued a clinical hold on the company’s Phase 3 study of metadoxine extended release (MDX) in adult...

CRH Medical

RBC starts CRH Medical at outperform

RBC Capital Markets initiated coverage of CRH Medical (NYSE MKT:CRHM; TSX:CRH) with an “outperform” rating and price target of $6.50 (Canadian). The stock closed at $5.50 on Wednesday. Analyst Doug Miehm writes that CRH...

IRadimed

Roth downgrades iRadimed to neutral

Roth Capital Partners downgraded iRadimed (NASDAQ:IRMD) to “neutral” from “buy” with a new price target of $11.50 after the company pre-announced a third quarter miss and reduced its 2016 outlook. The stock closed at...

Sorrento Therapeutics

Roth starts Sorrento Therapeutics at buy

Roth Capital Partners launched coverage of Sorrento Therapeutics (NASDAQ:SRNE) with a “buy” rating and $15 price target. The stock closed at $7.74 on Friday. Sorrento has a proprietary fully human antibody library...

Fortress Biotech

Roth starts Fortress Biotech at buy

Roth Capital Partners initiated coverage of Fortress Biotech (NASDAQ:FBIO) with a “buy” rating and $9 price target. The stock closed at $2.97 on Friday. Fortress is dedicated to acquiring, developing and commercializing...

Arrowhead Pharmaceuticals

WB ups Arrowhead Pharma price target to $12

William Blair raised its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $12 from $9 after the company licensed exclusive worldwide rights to two preclinical cardiovascular programs to Amgen (NASDAQ:AMGN)...

BioTime

Ladenburg starts BioTime at buy

Ladenburg Thalmann has initiated coverage of BioTime (NYSE MKT, TASE:BTX) with a “buy” rating and $6 price target. The stock closed at $3.59 on Thursday. “We view BioTime as roughly halfway through a restructuring...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.